Clinical Trial Update: Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating rituximab therapy for anti-MAG neuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-mag Neuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Anti-MAG Neuropathy | Phase 3 | Status: RECRUITING